Antigen self-presenting dendrosomes swallowing nanovaccines boost antigens and STING agonists codelivery for cancer immunotherapy DOI
Jiaxuan Xia, Xing Chen, Meichen Dong

и другие.

Biomaterials, Год журнала: 2024, Номер 316, С. 122998 - 122998

Опубликована: Дек. 9, 2024

Язык: Английский

Immunological nanomaterials to combat cancer metastasis DOI

Yuanbo Pan,

Junjie Cheng, Yang Zhu

и другие.

Chemical Society Reviews, Год журнала: 2024, Номер 53(12), С. 6399 - 6444

Опубликована: Янв. 1, 2024

This review highlights recent advances in immunological nanomaterials against metastasis and summarizes various nanomaterial-mediated immunotherapy strategies.

Язык: Английский

Процитировано

20

Cancer vaccines in the clinic DOI Creative Commons

Morgan E. Janes,

Alexander P. Gottlieb,

Kyong Soo Park

и другие.

Bioengineering & Translational Medicine, Год журнала: 2023, Номер 9(1)

Опубликована: Окт. 27, 2023

Abstract Vaccines are an important tool in the rapidly evolving repertoire of immunotherapies oncology. Although cancer vaccines have been investigated for over 30 years, very few achieved meaningful clinical success. However, recent advances areas such antigen identification, formulation development and manufacturing, combination therapy regimens, indication patient selection hold promise to reinvigorate field. Here, we provide a timely update on status vaccines. We identify critically analyze 360 active trials according delivery vehicle, type, indication, other metrics, as well highlight eight globally approved products. Finally, discuss current limitations future applications translation

Язык: Английский

Процитировано

35

Precisely Activating cGAS‐STING Pathway with a Novel Peptide‐Based Nanoagonist to Potentiate Immune Checkpoint Blockade Cancer Immunotherapy DOI Creative Commons

Yumeng Xing,

Ao Peng, Jianhui Yang

и другие.

Advanced Science, Год журнала: 2024, Номер 11(15)

Опубликована: Янв. 17, 2024

As an essential intracellular immune activation pathway, the cGAS-STING pathway has attracted broad attention in cancer treatment. However, low bioavailability, nonspecificity, and adverse effects of small molecule STING agonists severely limit their therapeutic efficacy vivo application. In this study, a peptide-based agonist is first proposed, KLA screened out to activate by promoting mitochondrial DNA (mtDNA) leakage. To precisely block PD-1/PD-L1 multi-stimuli activatable peptide nanodrug (MAPN) developed for effective delivery PD-L1 antagonist (CVR). With rational design, MAPN achieved site-specific release CVR response multiple endogenous stimuli, simultaneously activating blocking ultimately initiating robust durable T cell anti-tumor immunity with tumor growth inhibition rate 78% extending median survival time B16F10 tumor-bearing mice 40 days. Overall, antimicrobial peptides, which can promote mtDNA leakage through damaging membranes, may be potential alternatives giving new insight design novel agonists. Furthermore, presents universal platform synergy peptides.

Язык: Английский

Процитировано

13

High Entropy 2D Layered Double Hydroxide Nanosheet Toward Cascaded Nanozyme-Initiated Chemodynamic and Immune Synergistic Therapy DOI
Chen Wang,

Fengying Yuan,

Zichao Yan

и другие.

Journal of the American Chemical Society, Год журнала: 2024, Номер unknown

Опубликована: Окт. 30, 2024

High-entropy nanomaterials (HEMs) are a hot topic in the fields of energy and catalysis. However, terms promising biomedical applications, potential therapeutic studies involving HEMs unprecedented. Herein, we demonstrated high entropy two-dimensional layered double hydroxide (

Язык: Английский

Процитировано

12

STING in Cancer Immunoediting: Modeling Tumor-Immune Dynamics Throughout Cancer Development DOI Creative Commons
Xiao Zhang, Yan Chen,

Xi Liu

и другие.

Cancer Letters, Год журнала: 2025, Номер 612, С. 217410 - 217410

Опубликована: Янв. 16, 2025

Язык: Английский

Процитировано

1

Boosting Antitumor Immunity via a Tumor Microenvironment‐Responsive Transformable Trifecta Nanovaccine DOI Creative Commons
Qiang Li, Meng Dang, Junwu Tao

и другие.

Advanced Functional Materials, Год журнала: 2024, Номер 34(26)

Опубликована: Янв. 9, 2024

Abstract In situ tumor vaccines (ISTVs) hold great potential in immunotherapy, however, three major obstacles, including inadequate endogenous antigen uptake by dendritic cells (DCs), weak T‐cell immune responses, and stubborn immunosuppressive microenvironment (TME), still need to be fully addressed. Herein, a trifecta nanovaccine (TriNV) with TME‐responsive transformable ability is developed tri‐boost antitumor immunity. First, sufficient tumor‐associated antigens (TAAs) are liberated after immunogenic cell death induced via TriNV‐based photoimmunotherapy. the TME, soft‐transformed TriNV improves of TAAs DCs enhance acquired Second, self‐adjuvating released Mn 2+ synergistically promote DC maturation macrophage M1 polarization augmenting stimulator interferon genes activation further amplify responses. Moreover, decomposition MnO 2 within core exhausts glutathione facilitates O release alleviate hypoxia thereby overcoming chemical obstacles TME mitigate immunosuppression. Thus, remarkably eradicates primary tumors inhibits distant metastasis, thus demonstrating as feasible effective ISTV nanoplatform for combating poorly solid tumors.

Язык: Английский

Процитировано

6

STING-activating dendritic cell-targeted nanovaccines that evoke potent antigen cross-presentation for cancer immunotherapy DOI Creative Commons

Nguyen Thi Nguyen,

Xuan Thien Le,

Woo Tak Lee

и другие.

Bioactive Materials, Год журнала: 2024, Номер 42, С. 345 - 365

Опубликована: Сен. 6, 2024

Язык: Английский

Процитировано

5

Prospects for the Use of Metal-Based Nanoparticles as Adjuvants for Local Cancer Immunotherapy DOI Creative Commons
Irina Naletova, Barbara Tomasello, Francesco Attanasio

и другие.

Pharmaceutics, Год журнала: 2023, Номер 15(5), С. 1346 - 1346

Опубликована: Апрель 27, 2023

Immunotherapy is among the most effective approaches for treating cancer. One of key aspects successful immunotherapy to achieve a strong and stable antitumor immune response. Modern checkpoint therapy demonstrates that cancer can be defeated. However, it also points out weaknesses immunotherapy, as not all tumors respond co-administration different immunomodulators may severely limited due their systemic toxicity. Nevertheless, there an established way through which increase immunogenicity immunotherapy-by use adjuvants. These enhance response without inducing such severe adverse effects. well-known studied adjuvant strategies improve efficacy metal-based compounds, in more modern implementation-metal-based nanoparticles (MNPs), are exogenous agents act danger signals. Adding innate activation main action immunomodulator makes capable eliciting robust anti-cancer The has peculiarity local administration drug, positively affects its safety. In this review, we will consider MNPs low-toxicity adjuvants could provide abscopal effect when administered locally.

Язык: Английский

Процитировано

11

Nanoparticle targeting cGAS-STING signaling in disease therapy DOI
Zhou Lan,

Yu Huang,

Yuzhang Wu

и другие.

Nano Research, Год журнала: 2024, Номер 17(8), С. 7315 - 7336

Опубликована: Июнь 15, 2024

Язык: Английский

Процитировано

4

A Biomimetic Autophagosomes‐Based Nanovaccine Boosts Anticancer Immunity DOI
Liping Qu,

Guanhong Cui,

Yinping Sun

и другие.

Advanced Materials, Год журнала: 2024, Номер unknown

Опубликована: Авг. 28, 2024

Personalized cancer vaccines based on tumor cell lysates offer promise for immunotherapy yet fail to elicit a robust therapeutic effect due the weak immunogenicity of antigens. Autophagosomes, obtained from pleural effusions and ascites patients, have been identified as abundant reservoirs neoantigens that exhibit heightened immunogenicity. However, their potential personalized constrained by suboptimal lymphatic-targeting performances challenges in antigen-presenting endocytosis. Here,a reinforced biomimetic autophagosome-based (BAPs) nanovaccine generated precisely amalgamating autophagosome-derived two types adjuvants capable targeting lymph nodes is developed potently antitumor immunity. The redox-responsive BAPs facilitate cytosolic vaccine opening within cells, thereby exposing antigens stimulate strong immune response. evoke broad-spectrum T-cell responses, culminating effective eradication 71.4% established tumors. Notably, vaccination triggers enduring responses confer protection, with 100% mice shielded against rechallenge significant reduction incidence 87.5%. Furthermore, synergize checkpoint blockade therapy inhibit growth poorly immunogenic breast model. approach presents powerful formula high versatility immunotherapy.

Язык: Английский

Процитировано

4